Investors & Media

• Investor Relations
• Corp. Governance
• Board of Directors
• Events
• Quarterly Results
• Annual Reports
• Press Releases
• SEC Filings
• Stock Information
• IRS Form 8937
• Historic Lookup
• Analyst Coverage
• Contact IR

INVESTOR TOOLS

XOMA Corporation (Nasdaq: XOMA) is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for serious unmet medical needs. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government, and has licensed certain of its fundamental technologies to more than 60 companies.

XOMA's objective is to commercialize its products in the U.S. for markets that can be addressed with a targeted sales and marketing organization. The company's flagship product is gevokizumab (formerly known as XOMA 052), a humanized antibody to interleukin-1ß (IL-1 ß) with potential for the treatment of the inflammatory cause of multiple diseases. XOMA also has a pipeline of product candidates directed primarily at metabolic diseases, and a U.S. government-funded biodefense business.

In 2010, Les Laboratoires Servier, France's leading independent pharmaceutical company, partnered with XOMA for gevokizumab development. This collaboration brings together Servier's resources and expertise in pharmaceutical product development and commercialization with XOMA's biologics clinical development and manufacturing capabilities.

Today, XOMA's principal activities are centered on the advancement of gevokizumab, its preclinical pipeline and its biodefense business.

• Gevokizumab has been evaluated in Phase 1 and 2 clinical trials involving approximately 500 treated patients. In these trials, XOMA 052 was well-tolerated and demonstrated clinical efficacy in a seven-patient proof-of-concept study in vision-threatening Behçet's uveitis, an orphan indication.
  
  Based on these results and available data from clinical evaluations of other IL-1 pathway-inhibiting biologics, XOMA believes that gevokizumab has considerable clinical and commercial potential. XOMA plans to initiate Phase 3 development of gevokizumab in non-infectious uveitis involving the intermediate and/or posterior segments of the eye (NIU)., including Behçet's uveitis.
  
  
• XOMA's preclinical pipeline of novel antibodies includes the XMetA and XMetS classes of antibodies that modulate the insulin receptor for the treatment of diabetes and metabolic syndrome, and programs targeting validated oncology targets.
  
  
• Antibodies against botulinum toxins, led by XOMA 3AB, a novel combination of three antibodies to prevent and treat botulism poisoning caused by exposure to botulinum neurotoxin Type A, among the most deadly bioterror threats. XOMA 3AB is in a Phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Development of these antibodies has been funded in whole or in part with funds from NIAID, NIH, Department of Health and Human Services under Contract No. HHSN266200500004C, Contract No. HHSN266200600008C, Contract No. HHSN272200800028C, Contract No. HHSN266200600011C, Contract No., HHSN272200800026C, and Contract No.HHSN2722011031C.
  
  
• As a result of a previous development collaboration between Novartis and XOMA, Novartis is developing HCD122, a monoclonal antibody to CD40 currently in Phase 1/2 clinical trials for the treatment of lymphoma, and LFA102, a monoclonal antibody to the prolactin receptor for the treatment of certain cancers.

XOMA's antibody technology platforms include an unmatched collection of antibody phage display libraries and proprietary Human Engineering™, Bacterial Cell Expression (BCE), affinity maturation and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. Overall, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are currently in clinical development. XOMA is entitled to development-related milestones and royalties on antibodies covered under these licenses.